The aim of this prospective study was to investigate the feasibility of reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (SCT) in 37 adults with high-risk acute lymphoblastic leukemia (ALL) in first (n ¼ 30) or second (n ¼ 7) complete remission (CR). All patients were treated with fludarabine (150 mg/m 2 ) and melphalan (140 mg/m 2 ) followed by transplantation from matched sibling (n ¼ 27) or unrelated (n ¼ 10) donors. The indications for reduced-intensity conditioning allogeneic SCT (RIC-SCT) were as follows: (1) X50 years, 16 (43.2%) and (2) decreased organ function or active infections, 21 (56.8%). Graft-versus-host disease (GVHD) prophylaxis consisted of calcineurin inhibitor (cyclosporine for sibling and tacrolimus for unrelated transplants) and methotrexate. The cumulative incidence of acute (grades II-IV) and chronic GVHD was 43.2 and 65.6%, respectively. After a median follow-up of 36 months for surviving transplants, the 3-year relapse, non-relapse mortality, disease-free survival and overall survival rates were 19.7, 17.7, 62.6 and 64.1%, respectively. Transplants in first CR showed better transplantation outcomes than those in second CR. The potential of antileukemic activity of chronic GVHD was also found. This study suggests that RIC-SCT is a potential therapeutic approach for adults with high-risk ALL in remission who are ineligible for myeloablative transplantation.
Introduction
Advances in the chemotherapeutic treatment of adult acute lymphoblastic leukemia (ALL) have resulted in complete remission (CR) rates of 78-93%, but only 35% of these patients achieve long-term disease-free survival (DFS). [1] [2] [3] As the high incidence of relapse is a main cause of treatment failure in adults with ALL, optimal post-remission therapy, in particular, the efficacy of allogeneic stem cell transplantation (SCT) is a critical issue. Allogeneic SCT represents a curative treatment option for certain high-risk patients, such as those with Philadelphia chromosome (Ph)-positive ALL. [3] [4] [5] [6] However, SCT is associated with significant morbidity and mortality because of the toxicity of the conditioning regimen, graft-versus-host disease (GVHD), and the immune deficiency state that accompanies the procedure. These risks are significantly increased with advanced age and concurrent medical problems limiting myeloablative SCT in younger patients in good medical condition.
Reduced-intensity conditioning allogeneic SCT (RIC-SCT) is being used increasingly for patients who are considered the poor candidates for myeloablative conditioning because of their advanced age or other concurrent medical conditions. [7] [8] [9] [10] This strategy decreases the risk of non-relapse mortality (NRM) while preserving graft-versus-leukemia (GVL) effect. However, the role of RIC-SCT in adult ALL remains unclear because the interpretation of transplantation outcome is mainly limited by the retrospective nature of studies with the small number of patients and by the criteria used to select patients for transplantation. [11] [12] [13] [14] After 2000, several factors could account for the improved transplantation outcome in adult ALL. These factors include the development of supportive care facilities, the improvement of human leukocyte antigen (HLA) typing methods and the incorporation of targeted agents into conventional treatment regimens. [15] [16] [17] Considering the progress in adult ALL therapy, a detailed analysis is needed to clarify the role of RIC-SCT. We performed a prospective phase 2 study to estimate the potential role of RIC-SCT from a matched sibling or an unrelated donor for adults with high-risk ALL in first or second CR who are ineligible for myeloablative conditioning SCT.
Patients and methods

Patients and entry criteria
Between July 2000 and June 2007, we transplanted 37 consecutive adults (aged 15 years or older) with high-risk ALL after RIC from a matched sibling (n ¼ 27) or unrelated (n ¼ 10) donor. All patients aged between 50 and 65 years were eligible for the study (n ¼ 16; 43.2%). Patients o50 years of age were included if they had decreased organ function and/or if they had active infections that excluded them from myeloablative allogeneic SCT (n ¼ 21; 56.8%) ( Table 1) . Exclusion criteria included patients with advanced pretransplantation disease status (4second CR, relapsed, or refractory) or patients in remission without a high-risk factor, a creatinine more than twice the upper limit of normal, severe liver dysfunction (liver failure, cirrhosis or a total bilirubin 43 mg per 100 ml), corrected pulmonary diffusion capacity of o40%, cardiac ejection fraction of o35%, Karnofsky performance status of o50%, active central nervous system involvement of disease, serological evidence of infection with the human immunodeficiency virus or a positive pregnancy test. No exclusions were made for active bacterial or fungal infections, although fungal pneumonitis needed to be stable or to have improved after 4 weeks of azole therapy.
The main clinical and biological features presenting at the time of diagnosis are summarized in Table 1 . Median patient age was 45 years (range: 15-63 years). All patients had at least 1 of the following high-risk factors: (1) Ph (n ¼ 16; 43.2%) or t(4;11) (n ¼ 4; 10.8%); (2) high presenting leukocyte counts (X30 Â 10 9 /l for B-precursor ALL, X100 Â 10 9 /l for T-precursor ALL) (n ¼ 16; 43.2%) or (3) CR requiring more than 28 days of induction therapy (n ¼ 13; 35.1%). 18 Clinical and biological features presenting at transplantation are summarized in Table 2 . Thirty patients (81.1%) were transplanted in first CR and seven (18.9%) in second CR. All donor-recipient pairs were HLAtyped by using high-resolution genotyping for both HLA class I (HLA-A, -B and -C) and II (HLA-DRB1) antigens. Thirty-one patients (83.8%) were transplanted from a fully matched sibling (n ¼ 27) or an unrelated (n ¼ 4) donor, and the remaining six (16.2%) patients were transplanted from p2-allele mismatched unrelated donors. The stem cell source was granulocyte-colony stimulating factor mobilized peripheral blood in 34 patients (91.9%) and bone marrow in three (8.1%) patients.
All patients and donors provided written informed consent, and the treatment protocol was approved by the institutional review board of The Catholic University of Korea.
Treatment before transplantation
Induction chemotherapy was started with hyper-fractionated cyclophosphamide (300 mg/m 2 , every 12 h, days 1-3), vincristine (1.4 mg/m 2 , maximum dose 2 mg, days 4-11), idarubicin (12 mg/m 2 , days 4-11) and dexamethasone (40 mg, days 1-4 and days [11] [12] [13] [14] , which was mainly based on the hyper-CVAD (cyclophosphamide, vincristine, adriamycin and dexamethasone) regimen. 19 Subsequently, after the recovery of leukocyte (43 Â 10 9 /l) and platelet (460 Â 10 9 /l) counts, patients in CR received consolidation chemotherapy consisting of high-dose cytarabine (2 g/m methasone) was reduced by 25% in patients aged between 50 and 59 years; and by 50% in patients 60 years or older. During the consolidation phase, serious toxicities (Xgrade 3 nonhematological toxicities) required subsequent dose reductions of 25-50% at the attending physician's discretion. Central nervous system prophylaxis was performed by intrathecally administering triple agents (methotrexate 10 mg, cytarabine 40 mg and methylprednisolone 50 mg; six times in total).
In addition, patients with Ph-positive ALL received imatinib interim therapy before SCT, as described earlier. 15 Briefly, after induction chemotherapy (same as above), the first 4-week imatinib therapy was started. Patients who achieved CR after induction received the imatinib therapy at a daily dose of 400 mg. Patients not in CR received 600 mg imatinib daily. Subsequently, patients in CR received consolidation chemotherapy (same as above) followed by the second 4-week imatinib therapy (400 mg/day) bridging the time to SCT. Patients not in CR received the same schedule of imatinib (600 mg/day) after salvage chemotherapy (same as above).
Conditioning regimen and GVHD prophylaxis
All patients were given a RIC regimen consisting of fludarabine (30 mg/m 2 /d, days À8, À7, À6, À5 and À4) and melphalan (70 mg/m 2 /d, days À3 and À2). Antithymocyte globulin (2.5 mg/kg; SangStat, Lyon, France) was administered to six patients who received allele-mismatched unrelated grafts. GVHD prophylaxis was attempted by administering calcineurin inhibitor (cyclosporine for all sibling transplants and tacrolimus for all unrelated transplants) plus methotrexate (10 mg/m 2 on days 1, 3, 6 and 11). Calcineurin inhibitors were administered intravenously (cyclosporine 3 mg/kg/day and tacrolimus 0.03 mg/kg/day) as a continuous infusion from day À1. Subsequently, when patients were able to tolerate oral administration, they received calcineurin inhibitors orally (cyclosporine 6 mg/kg/day and tacrolimus 0.12 mg/kg/day) until day 60 (for all sibling transplants) or day 90 (for all unrelated transplants). The dose of calcineurin inhibitors was then gradually tapered and discontinued within 2-3 months after SCT. If residual leukemia was detected in the absence of acute GVHD during the follow-up period after SCT, calcineurin inhibitors were rapidly discontinued. Acute GVHD was treated with high-dose steroids, and extensive chronic GVHD was treated with calcineurin inhibitors and steroids.
Definitions
Neutrophil engraftment was defined to have occurred on the first of 3 consecutive days during which the absolute neutrophil count was 40.5 Â 10 9 /l. Platelet engraftment was defined to have occurred on the first of 7 consecutive days with a platelet count of 420 Â 10 9 /l, without transfusion support. GVHD was diagnosed and graded using an earlier published criteria. 20 Complete remission was defined as the reconstitution of normal bone marrow cellularity with o5% leukemic blasts, together with an absolute neutrophil count of 41.5 Â 10 9 /l and a platelet count of 4100 Â 10 9 /l. Relapse was defined by the reappearance of 45% leukemic cells in bone marrow aspirates or extramedullary leukemia in patients with earlier documented CR. Patients were considered refractory if peripheral blood blasts or extramedullary disease had not been eliminated, or if bone marrow blasts had not been reduced o5%, or both.
Statistical analysis
The main end points of this study were overall survival (OS), DFS, NRM and relapse. We calculated OS from the date of transplantation until the date of death or last follow-up. When calculating DFS, both relapses and deaths in remission were counted as adverse events. 21, 22 On the other hand, NRM and relapse were calculated by using cumulative incidence estimates and by taking into account the competing risk structure. 23 NRM was defined as death occurring in relapse-free patients. Patients alive without relapse at their last follow-up were censored with adjusting for relapse as a competing risk event. When calculating relapse incidence, relapse was an adverse event and patients alive without relapse at last follow-up were censored with adjusting for death without evidence of relapse as a competing risk event. Acute and chronic GVHD were considered as time-dependent covariates and their incidences were also calculated by using cumulative incidence estimates. 23 Survival curves for OS and DFS were plotted using the Kaplan-Meier method and compared by the log-rank test, 21, 22 whereas those for NRM and relapse were plotted by the cumulative incidence estimates and compared by the Gray test. 23 The prognostic significances of presenting and transplant covariates affecting OS and DFS were determined using the Cox proportional hazard model, including variables with a P-value o0.1 in earlier univariate testing. The assumption of proportional hazards over time was tested for all explanatory covariates by using a time-dependent covariate. Factors were considered significant if they had an associated P-value of o0.05 as determined by the likelihood ratio test, using 2-tailed significance testing. On the other hand, the prognostic significances of covariates affecting NRM and relapse were determined using the semi-parametric model called 'proportional hazard model for the sub-distribution of competing risks.' 23 Statistical analyses were performed using SPSS 13.0 software (SPSS, Chicago, IL, USA) with the exception of the cumulative incidence analyses, which were carried out with R (freely distributed on the web, http://www.r-project.org/).
Results
Engraftment and GVHD
All but three patients, who died before engraftment, were assessed for hematological reconstitution. Neutrophil recovery occurred in all patients at a median of 12 days (range, 9-20 days), and platelet recovery occurred at a median of 13 days (range, 7-23 days) after transplantation. There were neither primary nor secondary engraftment failures. Sixteen patients developed grades II through IV acute GVHD (11 grade II, three grade III and two grade IV). The cumulative incidences were 43.2±8.3%. Of the 32 patients who survived at least 100 days with sustained engraftment after transplantation, 21 developed chronic GVHD (nine limited, 12 extensive), which resulted in a 3-year cumulative incidence of 65.6 ± 8.7% (Table 2) .
Overall transplantation outcome
After a median follow-up of 36 months (range: 12 þ to 96 þ months) for surviving transplants, 25 (67.6%; 19 sibling transplants, six unrelated transplants) remained alive and 24 (18 sibling transplants, six unrelated transplants) of the 25 remained in continuous CR. At the time of analysis (31 November 2008), 12 (32.4%) of the 37 patients had died. A total of six of these 12 died of causes other than leukemic relapse and the remaining six patients died of progressive leukemia. Seven patients (18.9%) relapsed at a median 7 months (range: 3-18 months) after transplantation. The 3-year cumulative incidence of relapse and NRM were 19.7 ± 6.9 and 17.7±6.9%, respectively, and the 3-year DFS and OS rates were 62.6 ± 8.5 and 64.1 ± 8.6%, respectively (Figure 1 ).
Factors affecting transplantation outcome
By univariate analysis, disease status at transplantation seems to be a dominant factor altering the clinical outcomes in all transplants. Transplants in first CR showed better outcomes than those in second CR in terms of relapse (14.8 ± 6.8 versus 55.6 ± 22.2%, P ¼ 0.07), DFS (71.6±8.7 versus 28.6±17.1%, P ¼ 0.02) and OS (74.7 ± 8.5 versus 21.4 ± 17.8%, P ¼ 0.01) (Table 3, Figure 2 ). The presence of chronic GVHD was also associated with lower relapse incidence (4.8 ± 4.8 versus 45.5 ± 16.0%, P ¼ 0.02) and improved DFS (82.3±9.8 versus 54.5±15.0%, P ¼ 0.05) in all transplants (Table 3, Figures 3a and b) . On the other hand, a separate analysis of the antileukemic activity of chronic GVHD for transplants only in first CR (n ¼ 30) tended to show lower relapse incidence (5.5±5.5 versus 33.3±16.8%, P ¼ 0.08) but no significant DFS advantage (85.0 ± 10.2 versus 66.7 ± 15.7%, P ¼ 0.48) ( Table 4 , Figures 3c and d ). There were no significant covariates affecting NRM.
Discussion
Experience with RIC-SCT for adult ALL is still very limited, although there has been a large number of studies performed in evaluating the role of RIC-SCT in patients with myeloid malignancies, multiple myeloma and low-grade lymphoma. 24 Until now, few studies were conducted to evaluate the role of RIC-SCT in adult ALL. [11] [12] [13] Arnold et al. 11 evaluated the feasibility of RIC-SCT in high-risk ALL and suggested that only patients transplanted in CR seem to have long-term DFS. In their study, four of 22 patients were alive and disease-free from 5 to 30 months after RIC-SCT, and these four surviving patients were in first or second CR at the time of transplantation. Another study with 27 ALL patients (four first CR, 234 first CR at transplantation) from Martino et al. 12 also showed the feasibility of RIC-SCT (relapse 49%, NRM 23%, OS 31% at 2 years). Hamaki et al. 13 investigated the efficacy of RIC-SCT in 33 ALL patients (13 first CR, 6 second CR and nine induction failure or relapse at transplantation) and suggested the presence of GVL effect. With a median follow-up of 11.6 months, the 1-year DFS and OS rates were 29.8 and 39.6%, respectively. However, all above studies had some shortcomings in common that were the retrospective nature of the small number of patients even with multicenter study, a short duration of follow-up, and various regimens for conditioning and GVHD prophylaxis. [11] [12] [13] In addition, those studies showed limited success in transplantation outcomes to provide definite conclusions regarding RIC-SCT for adult ALL. Recently, the EBMT (European Group for Blood and Marrow Transplantation) reported the results of multicenter retrospective study of 97 patients with a median 2.8 years follow-up, which concluded that RIC-SCT is a feasible therapeutic option for adult ALL, especially for those patients in first CR.
14 However, the EBMT report also had the shortcomings of a retrospective based registry analysis, including the possibility of selection bias in enrolling patients, and various regimens for conditioning and GVHD prophylaxis. From this point of view, the role of RIC-SCT in high-risk adult ALL must be validated in prospective trials with homogeneous treatment protocol.
Our prospective cohort included consecutive 37 adults with high-risk ALL in first or second CR, who were ineligible for myeloablative SCT, treated with homogeneous treatment protocol (treatment before transplantation, conditioning and GVHD prophylaxis), and followed with an adequate duration (median follow-up of 3 years) compared with earlier studies. [11] [12] [13] [14] Transplantation outcomes (relapse 19.7%, NRM 17.7%, DFS 62.6% and OS 64.1%) in this study are encouraging despite older age, co-morbidities and high-risk nature of disease, which can be translated into the feasibility of RIC-SCT in this group of patients. Compared with earlier reports of RIC-SCT for adult ALL (relapse 49-51%, NRM 23-30%, DFS 21-30% and OS 31-40%), [11] [12] [13] [14] this study showed better transplantation outcomes. The better outcomes in this prospective study that only Abbreviations: CR, complete remission; DFS, disease-free survival; EM, extramedullary; GVHD, graft-versus-host disease; OS, overall survival; Ph, Philadelphia chromosome; RIC-SCT, reduced-intensity allogeneic stem cell transplantation; WBC, white blood cell.
Cumulative incidence of relapse Probability of disease-free survival Probability of overall survival included patients at first or second CR revealed the importance of favorable disease status at transplantation compared with earlier reports that included considerable percentage of patients without remission. [11] [12] [13] [14] In this regards, Arnold et al. 11 suggested that only patients transplanted in CR could achieve a survival benefit from RIC-SCT. Martino et al.
12 also showed the marginal difference of relapse rate according to disease status at transplantation (33% in CR versus 60% in advanced, P ¼ 0.10). The recent EBMT data showed patients with first CR had lower NRM (18 versus 44%, P ¼ 0.01) and higher DFS (42 versus 7%, P ¼ 0.002) and OS (52 versus 20%, P ¼ 0.003) at 2 years than patients with more advanced phase, which empathized the importance of favorable disease status at transplantation. 14 The data from the City of Hope that mainly included patients at first or second CR (17 of 25 patients), who received a similar conditioning regimen (fludarabine plus mephalan) to ours, showed better outcomes as well (relapse 16%, NRM 29%, DFS 59% and OS 59% at 2 years). 25 It is noted that better clinical outcomes in patients with first CR than second CR were revealed in this study, which also emphasized the importance of disease status at transplantation. Other causes of better outcomes could be explained by successful application of front-line imatinib therapy for Ph-positive ALL, which is made up 43.2% of our cohort, and the use of an early discontinuation approach of calcineurin inhibitors to modulate the GVHD and the GVL effects. Altogether, the results of this study suggest that RIC-SCT could be a valid therapeutic option for high-risk adult ALL with low leukemic cell burden (that is, first CR) at the time of transplantation.
One of the key findings of our study was that the development of chronic GVHD was associated with lower relapse, which was translated into improved 3-year DFS in all transplants. A separate analysis for patients only in first CR at transplantation also tended to show a benefit of chronic GVHD in terms of cumulative incidence of relapse. Although the role of GVHDrelated GVL in adult ALL is still controversial, a close relationship between chronic GVHD and the GVL effect have been continuously reported in adult ALL. [26] [27] [28] Earlier, we reported an inverse relationship between chronic GVHD and a relapse in patients with ALL who underwent myeloablative SCT in remission. [29] [30] [31] In this study, we showed the antileukemic activity of chronic GVHD in terms of preventing leukemia recurrence in the setting of RIC-SCT, which could be another evidence for role of GVL effect in adult ALL in remission. However, these results should be interpreted with caution because of the small number of patients studied, the reduction of statistical power of chronic GVHD-related GVL effect in the setting of first CR, and the potential existence of undetected confounding factors. Nevertheless, our findings are supported by other RIC-SCT studies. 12, 14 Martino et al. 12 found that GVHD (acute GVHD grade II-IV and/or chronic GVHD) had a marginal GVL effect (1-year incidence of disease progression; 35 versus 70%, P ¼ 0.05). The recent EBMT data also found that chronic GVHD was positively related to survival (P ¼ 0.01). 14 One of possible hypothesis to explain the cause of poor outcomes of RIC-SCT in adult ALL without remission is that the GVHD-related GVL effect is considerably influenced by leukemic cell burden. To apply RIC-SCT successfully for patients with high-risk ALL to allow for emergence of an effective GVL effect, novel therapeutic strategies to prevent relapse are needed. Additional therapy before and after RIC-SCT, using novel agents including monoclonal antibodies against antigens expressed by leukemic cells and other targeted agents such as tyrosine kinase inhibitors in Ph-positive ALL, may succeed in eradicating residual leukemic cells. [15] [16] [17] 32, 33 In addition, an effort to amplification of the GVL effect through the minimal residual disease-based post-grafting immunomodulation may be a one way to reduce the rate of relapse (for example, low-dose or early discontinuation of immunosuppressants, preemptive DLI ± interleukin-2 activation). [34] [35] [36] [37] In summary, this prospective study suggest that RIC-SCT for patients with high-risk adult ALL is a potential therapeutic approach to provide the GVL effect to patients ineligible for myeloablative SCT, especially for those patients in remission. The presence of chronic GVHD results in lower relapse and better DFS, indicating a clinically important GVL effect. Further studies aimed at developing treatment strategies to reduce leukemia cell burden before transplantation and to enhance the post-grafting GVL effect are needed. Abbreviations: CR, complete remission; DFS, disease-free survival; EM, extramedullary; GVHD, graft-versus-host disease; OS, overall survival; Ph, Philadelphia chromosome; RIC-SCT, reduced-intensity allogeneic stem cell transplantation; WBC, white blood cell.
